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Abstract
Background: Human UMP/CMP kinase was identified based on its enzymatic activity in vitro. The role of this protein is
considered critical for the maintenance of pyrimidine nucleotide pool profile and for the metabolism of pyrimidine analogs
in cells, based on the in vitro study of partially purified enzyme and recombinant protein. However, no detailed study has
yet addressed the role of this protein in nucleotide metabolism in cells.
Methodology/Principal Findings: Two stable cell lines in which UMP/CMP kinase (mRNA: AF087865, EC 2.7.4.14) can be
either up-regulated or down-regulated were developed using Tet-On Gene Expression Systems. The amount and enzymatic
activity of UMP/CMP kinase extracted from these two cell lines can be induced up by 500% or down by 95–98%. The
ribonucleotides of endogenous pyrimidine as well as the metabolism of exogenous natural pyrimidine nucleosides and their
analogs were not susceptible to the altered amount of UMP/CMP kinase in these two stable RKO cell lines. The level of
incorporation of pyrimidine nucleoside analogs, such as gemcitabine (dFdC) and troxacitabine (L-OddC), into cellular DNA
and their potency in inhibiting cell growth were not significantly altered by up-regulation or down-regulation of UMP/CMP
kinase expression in cells.
Conclusions/Significance: The UMP/CMP kinase (EC 2.7.4.14) expressed in RKO cells is not critical for the phosphorylation of
(d)CMP and the maintenance of natural nucleotide pools. It also does not play an important role in the activation of dFdC
and L-OddC. The increase by 500% or decrease by 95–98% in the levels of UMP/CMP kinase do not affect steady state levels
of dFdC and L-OddC in RKO cells. Overall, the activity and possible mechanisms of recombinant UMP/CMP kinase expressed
in the in vitro system can not be extended to that of UMP/CMP kinase expressed in a cell system or an in vivo system.
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Introduction
The enzymatic activity of UMP/CMP kinase has been con-
sidered to be essential for a variety of biological processes including
RNA synthesis, DNA replication/repair, membrane phospholipids
synthesis and nucleotide metabolism in cells. The human UMP/
CMP kinase (mRNA: AF087865, EC 2.7.4.14) has been identified
based on its enzymatic activity catalyzing the phosphorylation of
CMP, UMP, dCMP and dUMP to their diphosphate nucleotides
using partially purified protein from cellular extract as well as its
recombinant protein [1–9]. The gene of this protein was found to
be located on chromosome 1. (1p34.1-p33). It was assumed that
this UMP/CMP kinase is responsible for the synthesis of CDP,
UDP and dCDP as well as the diphosphates of deoxycytidine/
deoxyuridine analog [2–9]. In the in vitro study, the efficiency of
this protein could be affected by different conditions of the enzyme
reaction, such as the concentration of DTT, Mg
+2 and ATP etc.
These could account for the difference of its properties among
different laboratories. For the recombinant protein, its Km values
for CMP, dCMP, UMP and dUMP are around 5–500 mM, 404–
1600 mM, 50–1600 mM and 1300–5900 mM, respectively; the Kcat
values for CMP, dCMP, UMP and dUMP are 1.7–248 s
21, 2.5–
216 s
21, 0.6–140 s
21 and 0.1–7.2 s
21, respectively, as summarized
in Table 1 [2,5,8,10]. The physiological concentrations of CMP,
dCMP, UMP and dUMP are around 34 mM, 0.3 mM, 184 mMa n d
2.2 mM, respectively, in cells [11]. The Michaelis-Menten kinetic
parameters organized in Table 1, however, exhibit much higher
Km values of this enzyme than the concentration of its natural
substrates in cells. Based on its enzymatic characteristics, this
enzymewouldbeinefficientincellsunlessotherassociated protein(s)
could improve its efficiency. If the amount of this protein is changed
or the protein is modified such as up-regulation, down-regulation,
phosphorylation, dephosphorlyation, glycosylation and methyla-
tion, it should affect the metabolism of nucleotides in cells. No
detailed study currently has yet addressed the role of this protein on
nucleotide metabolism in cells.
Deoxycytidine analogs and 5-Fluorouracil (5-FU) are used in
clinic for the treatment of certain tumors and viral infections.
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to their triphosphate forms before they can be incorporated into
cellular or viral DNA and/or RNA for anticancer and antiviral
effects. UMP/CMP kinase activity should be pivotal for the
cytotoxic effect of cytidine analogs in target cells because it is
responsible for the phosphorylation of these cytidine analog
monophosphates or 5-FU monophosphate to their diphosphate
metabolites in anticancer and antiviral therapy [2,5,7,9]. Gemci-
tabine (dFdC) and troxacitabine (L-OddC) are anticancer agents
that are currently being used or under clinical trials for the
treatment of cancer [12]. Although the configurations of dFdC
and L-OddC are different, the first two steps in their metabolism
appear to be the same. Both dFdC and L-OddC are phosphor-
ylated by the cytoplasmic deoxycytidine kinase to their respective
monophosphate metabolites, and the so-called UMP/CMP kinase
in vitro can phosphorylate dFdC and L-OddC monophosphates to
their diphosphate metabolites. Their in vitro Km values are 450–
581 mM with Vmax 3.6–31 mmol/mg/min and 1037 mM with
Vmax 0.63 mmol/mg/min, respectively [2,5]. There are many
enzymes involved in 5-FU metabolism, in which this UMP/CMP
kinase was thought to play an important role in the activation of
5-FU to 5FUTP/5FdUTP and its incorporation into RNA and
DNA [12].
Although the UMP/CMP kinase is suggested to be the enzyme
responsible forthephosphorylationof(d)CMPand (d)UMP aswellas
some cytidine analog monophosphates, there is little information in
cells to support the current dogma. The current knowledge indicated
that the KEGG (Kyoto Encyclopedia of Genes and Genomes)
metabolic pathway database has represented a network of interacting
molecules as well as compensatory and regulatory pathways during
pyrimidine metabolism in cells (http://www.genome.jp/kegg/
pathway/map/map00240.html). However, a gene is not functionally
identified until its phosphorylation target is identified or until the role
on the biochemical pathway is identified [13].
In this study, we try to evaluate the impact of UMP/CMP
kinase expressed in cells with respect to the metabolic and
regulatory pathways of pyrimidine and its analogs. Two RKO cell
lines were established in which the UMP/CMP kinase expression
could be regulated either up or down by doxycycline. The
intracellular ribonucleotide profile, pyrimidine nucleoside metab-
olism, dFdC and L-OddC metabolism, and their cytotoxicities
were studied by altering the amount of UMP/CMP kinase in cells.
Materials and Methods
Chemicals and cell line
CMP, dCMP, ATP and 5-FU were purchased from Sigma.
[5-
3H(N)] Cyd, [5-
3H(N)] dCyd, [5-
3H] L-OddC, [5-
3H] dFdC
were purchased from Moravek Biochemicals. The double-
stranded DNA oligonucleotide encoding the shRNA of UMP/
CMP kinase with the following sequences were used: 59-
(+)CACCCGGGGAAATGGATCAGACAATGGCGAACCAT-
TGTCTGATCCATTTCCC, 59-(2)AAAAGGGAAATGGAT-
CAGACAATGGTTCGCCATTGTCTGATCCATTTCCC (In-
vitrogen). RKO (human colorectal carcinoma) cells was a gift from
Dr. Edward Chu’s lab (Department of Internal Medicine, Yale
University).
Establishment of a stable cell line overexpressing UMP/
CMP kinase
The inducible Tet-On UMP/CMP kinase cell line was
established by using Tet-On Gene Expression System (Invitro-
gen). The procedures described in the user manual of the Tet-On
Gene Expression System were followed. RKO cells were
transfected using the regulator plasmid, pcDNA6/TR, which
expressed tetracycline repressor (TR) protein. After 48 hr, the
cells were grown in medium with 0.5 mg/mL blasticidin for
selecting cells with TR expression. The selected cells with TR
were further transfected using the pcDNA5/TO plasmids with
the coding sequence (mRNA: AF087865) of human UMP/CMP
kinase, the Tet-responsive element is between 59- BamH I and 39-
Xho I sites of pcDNA5/TO vector (Invitrogen). To isolate cells
with co-transfected constructs, selection medium with both
blasticidin and hygromycin at 0.5 mg/mL was added after
48 hr transfection. The selected cells were used for the study. To
induce the expression of UMP/CMP kinase, the cells grown in
5% serum-containing medium to 60% confluence were exposed
to various concentrations of doxycycline for 72 hr. UMP/CMP
kinase assays described below was used for evaluating the UMP/
CMP kinase activity. The data were analyzed by GraphPad
software.
Establishment of the stable cell line underexpressing
UMP/CMP kinase
To further explore the function of UMP/CMP kinase in cells,
RNAi technology was used to down-regulate the expression of
endogenous UMP/CMP kinase. BLOCK-iT
TM Inducible H1
RNAi Entry Vector, pENTR/H1/TO, (Invitrogen) was used to
generate a stable cell line that can be induced to express the short
hairpin RNA (shRNA) against UMP/CMP kinase. A double-
stranded DNA oligonucleotide generating a shRNA of UMP/
CMP kinase was cloned into the H1/TO RNAi cassette located
immediately downstream of the H1/TO pol III promoter. This
H1/TO pol III promoter contains two TetO2 sites for tetracy-
cline-regulated expression. The plasmid expressing shRNA was
Table 1. Kinetic properties of recombinant human UMP/CMPK with ATP as phosphate donor.
Substrates Km (mM) Vmax (mmol/mg/min) Kcat (s
21)
CMP 500
a 20
b 15
c 5,29
d 4.2
a 350.0
b 232.0
c 513,620.0
d 1.7
a 140.0
b 92.0
c 205,248.0
d
dCMP 1600 1000 513 404,1388 602 213.5 65.0 288,540..0 2.5 85.4 14.0 115,216.0
UMP 1600 50 67 N.D 1.6 350.0 218.0 N.D 0.6 140.0 87.8 N.D
dUMP 5900 1300 N.D N.D 0.1 17.9 N.D N.D 0.1 7.2 N.D N.D
The average values were summarized from the data reported by
aVan Rompay et al, 1999;
bAlexandre et al, 2007;
cLiou et al, 2002;
dHsu et al, 2004 in the different enzyme assay condition.
doi:10.1371/journal.pone.0019490.t001
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To isolate stable cells with down-regulated UMP/CMP kinase
effectively, the transfected cells were diluted 1:60 into fresh
medium for 48 hr, and then the selection medium was added. At
all times, cells were grown in the presence of 0.75 mg/mL Zeocin
for selection. To induce the expression of shRNA, the method
used is similar to the one described above for overexpressing
UMP/CMP kinase.
Preparation of cell extract, UMP/CMP kinase Assays,
Western blotting and immunostaining
All cell extracts were obtained as described [14]. The protein
concentration of cell extracts was determined by using the Bio-
Rad protein assay (Bio-Rad) and absorbance was read at
595 nm on kinetic microplate reader (Molecular Devices
Corporation). The enzyme assays have been described previ-
ously [10]. In this study, we used the optimum condition for
CMP and dCMP, respectively. The enzyme reaction was
performed with 1 mM concentrations of substrates in the buffer
containing 50 mM Tris-HCl, pH 7.5, 10 mM NaF, 25 mM
NaCl, 2 mM dithiothreitol (DTT), 0.5 mM EDTA in which the
ratios of ATP: Mg are 2:2 mM for CMPK assay and 1:2 mM
for dCMPK assay. The supernatant part of cell lysates was
loaded onto 12% SDS-PAGE gels, and then transferred onto
pure nitrocellulose membrane (Bio-Rad) for Western blot assay.
The blot was then incubated with the specific UMP/CMP
kinase antibody [5], 3-phosphoglycerate kinase (PGK) recog-
nized by PGK antibody [15] was used as the internal control.
For the immunostaining of UMP/CMP kinase protein in cells,
the procedure was carried out as previously described [16]. The
UMP/CMP kinase antibody and Alexa Fluor 488 goat anti-
rabbit IgG (Invitrogen) were used for the primary and secondary
staining. The HSP27 protein was used as a control in co-
localization studies using anti-HSP27 (Cell signaling) and Alexa
Fluor 546 goat anti-mouse IgG (Invitrogen).
Ribonucleotide pool assay
Endogenous nucleotide pool profiles were evaluated by
increasing or decreasing the amounts of UMP/CMP kinase in
cells. Cells with up-regulated or down-regulated UMP/CMP
kinase were cultured in the 10% serum-containing medium with
0–2.0 ng/mL or 0–10.0 ng/mL doxcycline, respectively, for
72 hr. Cells were collected and treated with 15% trichloroacetic
acid on ice for 10 min after being washed with ice-cold
phosphate-buffered saline (PBS) containing 20 mM dipyridamole
(Sigma) to obtain extracts. High pressure liquid chromatography
(HPLC) with Partisil SAX column (Whatman) was used to assess
the ribonucleotide profiles of the cellular supernatant extract
treated with a 45:55 ratio of trioctylamine and 1,1,2-trichlorotri-
fluroethane. The trichloroacetic acid insoluble pellet containing
the nucleotide that has incorporated into the DNA was washed
twice and resolubilized in Me2SO prior to evaluation on a
Beckman LS5000TD scintillation counter. Results are based on
the mean and standard deviation of at least three independent
experiments.
Metabolism of Cyd, dCyd, L-OddC and dFdC in cells
overexpressing or underexpressing UMP/CMP kinase
The metabolism of radiolabeledC y d ,d C y da n dt h e i ra n a l o g s
was studied with the following procedures, which is a
modification of the previously established protocol [16]. Briefly,
the cells overexpressing and underexpressing UMP/CMP kinase
were seeded at 5610
5 cells per culture dish, respectively. For the
overexpression, doxycycline at 0, 0.4 and 2.0 ng/mL was added
to the respective cells to induce UMP/CMP kinase; for
underexpression, doxycycline 0, 1.0 and 10 ng/mL was added
to respective cells to induce the shRNA of UMP/CMP kinase in
order to down-regulate UMP/CMP kinase. After 72 hr, 1 mM
[5-
3H] Cyd (2.3 Ci/mmol), 1 mM[ 5 -
3H] dCyd (2.0 Ci/mmol),
2 mM[ 5 -
3H] L-OddC (0.4 Ci/mmol) or 2 mM[ 5 -
3H] dFdC
(0.4 Ci/mmol), was added to cells induced by doxycycline,
respectively, for indicated times. Parallel cultures were incubat-
ed with non-radiolabeled materials at same concentrations for
calculating cell number. At the end of incubation with the
radiolabeled materials, cells were harvested for making a crude
cell extract. The cell supernatant and insoluble pellets then were
further treated for HPLC assay and DNA incorporation analysis
with the procedures described above.
Growth inhibition assay
Growth inhibitory effects of the compounds were assessed by
measuring the inhibition of cell proliferation. The experimental
procedures have been described previously [17]. Briefly, RKO
cells with overexpressing and underexpressing UMP/CMP kinase
were pre-treated with or without doxycycline at different
concentration for 72 hr. Then 10
4 cells/mL in the logarithmic
growth phase were seeded in 24-well plates and treated with dFdC
(0–13 nM), L-OddC (0–600 nM) and 5-FU (0–20 mM). After
maintaining the culture for 72 hr, the cell monolayer was then
washed twice with PBS and stained with 0.5% methylene blue in
50% ethanol. The cell layer was washed with water, dried, and
solubilized in 1% N-lauroyl-sarcosine (Sigma). The protein
concentration was determined by reading A595 nm on an
automated microplate reader (Bio-Tek Instrument, Inc.). The
potency of the compounds examined for cell growth inhibition was
then determined by comparing the treated wells with the
untreated control wells.
Results
Evaluation of cells with up-regulated and
down-regulated UMP/CMP kinase systems
To determine whether UMP/CMP kinase affects the nucleo-
tide metabolism and the phosphorylation of deoxycytidine
analogs, we have established two stable cell lines in which
UMP/CMP kinase can be up-regulated and down-regulated,
respectively. Under non-inducted condition, the protein levels
and enzymes activities of UMP/CMP kinase in cells with the up-
regulated system are comparable to that of control cells.
However, we observed that the protein expression of UMP/
CMP kinase dropped down and the enzyme activities reduced
conversion by 93% for CMP and 96% for dCMP in cells with
shRNA-mediated knockdown under non-induced condition. This
could be due to the leakage of the H1 promoter which has been
reported by others [18]. We also found out that the longer time in
culture, the more leakage occurs. No change in protein amount
was found in parental RKO cells with/without doxycycline
treatment. (Fig. 1Aa). The digital images of cells demonstrated
the subcellular localization of UMP/CMP kinase. Although the
amount of enzyme can not be exactly measured by the technique
of confocal microscope, the expression of UMP/CMP kinase was
clearly overexpressed in cells with the up-regulated UMP/CMP
kinase system after doxycycline induction. In down-regulated
UMP/CMP kinase cells, the images show that the expression of
UMP/CMP kinase has reached a base line level as compared
with control cells (Fig. 1B).
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metabolism of exogenous Cyd and dCyd are not affected
by overexpressing or underexpressing UMP/CMP kinase
in cells
The cell lines with up-regulated or down-regulated UMP/CMP
kinase system induced by doxycycline were used to evaluate the
impact of UMP/CMP kinase on endogenous pools of ribonucleoside
diphosphate and triphosphate in cells. The UMP/CMP kinase
induced by doxcycline was monitored by enzyme assay and Western
blot analysis. In the in vitro assays, as shown in Fig. 1C,D, different
protein levels and activities of UMP/CMP kinase were observed in
non-induced cells (control group) between both cell lines. The
enzymatic activities (Fig. 1 Cb,Db) and the amount (Fig. 1 Ca,Da) of
UMP/CMP kinase in the cell extracts from the two cell lines are
dependent on the different concentrations of doxycycline and show a
maximum alteration of around 500% over no doxycycline induction.
In cells with 500% UMP/CMP kinase increase or in cells with total
95–98% decrease, i.e. leaky 93–96% plus inducible 2% (Fig. 1), there
is no alteration on the profiles of the purine and pyrimidine
ribonucleotides (Fig. 2 Aa,Ba). The metabolism of exogenous Cyd
a n dd C y dw e r ee x a m i n e di nt h e s et w oc e l ll i n e s .T h ea m o u n to f
diphosphate or triphosphate metabolite of Cyd or dCyd is not
affected by altering the amount of UMP/CMP kinase in cells (Fig. 2
Ab,Bb). In the system down-regulating UMP/CMP kinase, the level
of dCyd monophosphate in non-induced cells is higher compared to
that in the system up-regulating UMP/CMP kinase. It can not be
excluded that the shRNA nonspecifically targets another protein. No
change in dCyd metabolites, however, was found after doxycycline
induction as compared with non-induced cells. Therefore, overex-
pression and underexpression of UMP/CMP kinase do not have a
major impact on the incorporation of Cyd and dCyd into RNA or
DNA (Fig. 2 Ab,Bb).
Figure 1. Protein amount and enzymatic activity of UMP/CMPK in cellular extract from RKO cells. Doxycycline induces the
overexpression or underexpression of UMP/CMP kinase. Specific antibodies of UMP/CMP kinase and PGK were used to detect the proteins of UMP/
CMP kinase and PGK, respectively, for Western Blot. Aa. parental RKO cells with or without doxycycline induction. RKO-CMPK (cells with up-regulated
UMP/CMP kinase system) and RKO-shRNA (cells with down-regulated UMP/CMP kinase system) without doxycycline induction. Ab. (d)CMP kinase
assays for parental RKO cells, RKO-CMPK and RKO-shRNA cells without doxycycline induction. B. confocal microscopy images of cells induced by
different concentration of doxycycline, which show the localization of UMP/CMP kinase (green fluorescence) and HSP27 (red fluorescence). Parental
RKO cells were used as control cells. C. overexpression of UMP/CMP kinase in RKO cells. a. expression of UMP/CMP kinase level was detected by
Western blotting. PGK is used as the internal control. b. enzyme activity of UMP/CMP kinase using CMP and dCMP as substrates. D. underexpression
of UMP/CMP kinase in RKO cells. a. expression of UMP/CMP kinase level was detected by Western blotting. PGK is used as the internal control.
b. enzyme activity of UMP/CMP kinase using CMP and dCMP as substrates.
doi:10.1371/journal.pone.0019490.g001
Figure 2. Evaluation of endogenous ribonucleotide pool profile and metabolism of exogenous Cyd and dCyd in RKO cells
overexpressing or underexpressing UMP/CMP kinase. Aa. the content of ribonucleoside di- and triphosphates in cells overexpressing UMP/
CMP kinase. Ab. the amounts of Cyd and dCyd metabolites as well as the amounts of their incorporation into DNA (PPT) in cells overexpressing UMP/
CMP kinase. Ba. the content of ribonucleoside di- and triphosphates in cells underexpressing UMP/CMP kinase. Bb. the amounts of metabolites of
Cyd and dCyd as well as the amounts of their incorporation into DNA (PPT) in cells underexpressing UMP/CMP kinase.
doi:10.1371/journal.pone.0019490.g002
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up-regulated and down-regulated UMP/CMP kinase cells
The effect of overexpressing or underexpressing UMP/CMP
kinase on the metabolism of dFdC and L-OddC was examined in
cells. Both sets of inducible cell lines were cultured in medium with
different concentrations of doxycycline for 72 hr, then treated with
2 mM dFdC or 2 mM L-OddC, respectively, for 6 hr. In cells with
500% increase or total 95–98% decrease in UMP/CMP kinase
expression, the dFdC metabolite levels remain unaffected. The
ratios of dFdC monophosphate to its diphosphate and triphos-
phate are also similar. The amount of dFdC triphosphate
incorporated into the DNA remained constant in comparison
with the control group in both cells overexpressing and under-
expressing UMP/CMP kinase (Fig. 3 A,C). The same results are
also observed for metabolism of L-OddC in both inducible cell
lines (Fig. 3 B,D).
Overexpression and underexpression of UMP/CMP kinase
do not influence the growth-inhibition activity of dFdC,
L-OddC and 5-FU in RKO cells
The objective of our study was to evaluate the efficiency of
intracellular UMP/MP kinase to facilitate the cytotoxic activities
of dFdC, L-OddC and 5-FU and the correlation of triphosphates
with the pharmacological activities of these drugs. For the up-
regulated UMP/CMP kinase cells in the presence of different
concentration of doxycycline (0, 0.4 and 2.0 ng/mL), compared
with the control group (doxycycline 0 ng/mL), results of 72 hr
growth-inhibition showed that the differential effects of doxycy-
cline used at 0.4 and 2.0 ng/mL dosages have not significant
change in all drug treatments. Two-way ANOVA analysis shows
that their P values are 0.849 and 0.091 for dFdC. For L-OddC,
the P values are 0.598 and 0.092. The P values are 0.760 and
0.069 for 5-FU. For the down-regulated UMP/CMP kinase cells
induced by doxycycline, the various dosages (2.0, 10.0 ng/mL) of
doxycycline have no significant effect for all drug treatments as
compared with control group. The P values of dFdC are 0.919 and
0.652. The P value of L-OddC are 0.391 and 0.392. The P values
of 5-FU are 0.379 and 0.305. As shown in Fig. 4, the inhibitory
potency on cell growth is not altered by change in amount of
UMP/CMP kinase in cells treated with drugs for 72 hr. The
results are consistent with the data shown in Fig. 3.
Discussion
Human UMP/CMP kinase was identified based on its
enzymatic activity in vitro. The majority of studies on mammalian
UMP/CMP kinase have been performed with partially purified
enzymes from different cells and tissues [2]. The cDNA of human
UMP/CMP kinase has been cloned, expressed and purified. The
recombinant protein has been used to study the phosphorylation
of both natural (d)CMP and their analogs. The crystal structure
further explained its kinetic properties for different substrates [19].
Its major biochemical characteristics based on enzymatic activities
in the in vitro system were summarized in Table 1. We have
established inducible UMP/CMP kinase cell lines as cell models in
Figure 3. The metabolism of dFdC and L-OddC in cells overexpressing or underexpressing UMP/CMP kinase. A. the content of dFdC
mono-, di- and triphosphate in cells overexpressing UMP/CMP kinase. B. the content of L-OddC metabolites in cells overexpressing UMP/CMP kinase.
C. the content of dFdC metabolites in cells underexpressing UMP/CMP kinase. D. the content of L-OddC metabolites in cells underexpressing UMP/
CMP kinase.
doi:10.1371/journal.pone.0019490.g003
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metabolism. We have focused on the metabolism of endogenous
and exogenous (d)cytidine as well as the activation of their
nucleoside analogs in cells. Our results indicated that either the
level of UMP/CMP kinase can be increased by 500% or
decreased by 95–98%. However, the natural triphosphate levels
of adenosine, guanosine, uridine and cytidine are not altered and
the metabolism of exogenous cytidine and deoxycytidine is not
Figure 4. Growth-inhibition activity of deoxycytidine analogs and 5-FU in cells up-regulating or dow-nregulating UMP/CMP kinase
expression. Aa,Ba,Ca. growth-inhibition activity of dFdC, L-OddC and 5-FU in cells up-regulating UMP/CMP kinase with different concentration of
doxycycline. Ab,Bb,Cb. growth-inhibition activity of dFdC, L-OddC and 5-FU in cells down-regulating UMP/CMP kinase with different concentration of
doxycycline.
doi:10.1371/journal.pone.0019490.g004
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between in vitro system and in cell system could be due to: (1) the
characteristic of recombinant UMP/CMP kinase protein ex-
pressed in E. coli may be different from that of the protein
expressed in cells. In the cell system, there is a major contribution
of post-translational modifications in cells to the expressed protein
for efficient secretion and stability. These protein modifications
include correct folding and aggregation, oxidation of methionine,
deamidation of asparagines and glutamine, variable glycosylation,
and proteolysis. In contrast, the recombinant proteins expressed in
bacteria undergo simple modifications. [20]. (2) The pathways of
nucleoside metabolism consist of complex molecular interaction
networks involving many enzymes of phosphorylation/dephos-
phorylation, molecular bindings and proteolysis, in addition to the
control of gene expression. On the KEGG metabolic pathway
map, the metabolism of (d)CMP currently consists of 104
functionally related enzymes (Supplementary Fig. S1). In cells
with overexpressed UMP/CMP kinase, the feedback regulation of
different enzymes and their products would balance the impact of
UMP/CMP kinase once it dominates the conversion from (d)CMP
to (d)CDP in the presence of doxycycline. In cells with under-
expressed UMP/CMP kinase, the conversion of (d)cytidine could
have many alternative pathways instead. Thus, the results
demonstrated that this UMP/CMP kinase, either expressed in
abundance or reduced to low levels, does not play a role on the
metabolism of pyrimidine or the maintenance of pyrimidine pool
profiles in RKO cells. Since the cellular pools are not sensitive to
UMP/CMP kinase, the up-regulation or down-regulation of
UMP/CMP kinase might have triggerd compensatory mecha-
nisms. These results indicated that the activities and possible
mechanisms of protein expressed in the in vitro system can not be
extended to that of UMP/CMP kinase protein expressed in a cell
system or an in vivo system.
Our observations also argue that this UMP/CMP kinase
interferes with the phosphorylation of dFdC and L-OddC. The
cytotoxycity data also support the metabolism observation and
show that the UMP/CMP kinase might not be critical for the
maintenance of steady state levels of dFdC, L-OddC and 5-FU in
cells. Interestingly, cell survival assay using a colony formation
reported by Liou et. al. [21] demonstrated that up-regulation and
down-regulation of UMP/CMP kinase protein lead to a change in
the cellular sensitivity to dFdC due to the increased formation of
total amount of diphosphate and triphosphate metabolites in
HeLa S3 and HCT-8 cells. However, one may assume that there is
another compensatory pathway to phosphorylate these nucleoside
analogs stepwise to their triphosphates. It is important to
understand the mechanism of the numerous anticancer and
antiviral deoxycytidine analogs which must be activated to their
respective triphosphates. In addition, molecular alterations also
may have the potential to affect cell survival after analogs
treatment. The dFdC in 100 nM concentration can effectively
induce the expression of p53 and Bax, and then lead to apoptosis in
RKO cells [22]; human apurinic/apyrimidinic endonuclease
(APE-1) exonuclease activity plays an important role in the
cytotoxicity of L-OddC [23]. Russo P et. al. demonstrated that the
cytotoxicity of 5-FU (0.01–10 uM) correlates with the status of p53
gene and Ras gene in ten human colon cancer cell lines [24].
Nucleoside analogs-mediated apoptosis, cytotoxicity and cell cycle
progression are influenced by p53 status, Ras, and APE-1 level in
cells. The up-regulation or down-regulation of UMP/CMP kinase
might be associated with these pathways. These observations may
explain the discrepancies between cytotoxicity and cell survival
assay in which cells were exposed to 5-FU (1–100 uM)
demonstrated by Humeniuk et. al. [25,26]. Furthermore, they also
suggested there could be a small impact on 5-FU sensitivity once
the amount of UMP/CMP kinase changes in cells.
In summary, the UMP/CMP kinase (EC 2.7.4.14) is not critical
for the phosphorylation of CMP, dCMP and maintenance of
natural nucleotide pools in cells. It also does not play an important
role in the activation of dFdC and L-OddC. The increase by
500% or decrease by 95–98% in its cellular levels does not affect
steady state levels of dFdC and L-OddC in RKO cells. Our
present results are not consistent with previous reference reports
since we expressed the protein in cell systems instead of in in vitro
systems. Overall, the activity and possible mechanisms of
recombinant UMP/CMP kinase expressed in the in vitro systems
can not be extended to that of UMP/CMP kinase expressed in a
cell system or an in vivo system.
Supporting Information
Figure S1 Pyrimidine metabolism pathway. This pathway
depicted by the KEGG was released on Oct. 19, 2010 at http://
genome.jp/kegg/pathway/map00240.html. The enzymes are
shown in boxes with the EC numbers inside. The circled box
represents the UMP/CMP kinase (EC 2.7.4.14), the recombinant
version of which was used in our study.
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